secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039047
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q2 2023 cash $157.1M, initiates BDC-1001 Phase 2, gets IND for BDC-3042
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $157.1M as of June 30, 2023; runway expected through 2025.
- First patients dosed in BDC-1001 Phase 2 dose-expansion study for HER2+ colorectal, endometrial, and gastroesophageal cancers.
- FDA cleared IND for BDC-3042 (Dectin-2 agonist) in July 2023; Phase 1 start expected later in 2023.
- Loss from operations $19.8M in Q2 2023 vs $23.1M in Q2 2022; R&D expenses reduced to $15.6M from $18.9M.
- Collaboration revenue flat at $1.4M; G&A essentially unchanged at $5.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023039047/0000950170-23-039047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023039047/bolt-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer